Neurocrine Biosciences (NBIX) Cash from Investing Activities (2010 - 2026)

Neurocrine Biosciences has reported Cash from Investing Activities for 17 years, with the latest figure at -$506.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 3664.79% year-over-year to -$506.2 million; the trailing twelve-month figure through Mar 2026 stood at -$784.8 million (down 1262.5% YoY), and the FY2025 full-year result was -$264.4 million, down 108.52% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$506.2 million, down from -$52.9 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $31.4 million in Q2 2022, with the low at -$506.2 million in Q1 2026.
• Historically, Cash from Investing Activities has averaged -$90.7 million across 5 years, with a median of -$55.0 million in 2024.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities jumped 134.58% — and 2026, when it sank 3664.79%.
• Neurocrine Biosciences' Cash from Investing Activities stood at -$115.6 million in 2022, then sank by 74.57% to -$201.8 million in 2023, then surged by 66.15% to -$68.3 million in 2024, then increased by 22.55% to -$52.9 million in 2025, then sank by 856.9% to -$506.2 million in 2026.
• The last three Cash from Investing Activities figures came in at -$506.2 million (Q1 2026), -$52.9 million (Q4 2025), and -$196.7 million (Q3 2025), per Business Quant data.